406213-76-1

Usage

Uses

Used in Chemical Synthesis:
N3-PEG6-tBu is used as a building block for the synthesis of various complex molecules and materials, thanks to its reactive azide group and t-butyl ester moiety. The stable triazole linkages formed through Click Chemistry allow for the creation of diverse molecular structures with potential applications in various fields.
Used in Drug Delivery Systems:
In the pharmaceutical industry, N3-PEG6-tBu is used as a component in the design of drug delivery systems. Its hydrophilic PEG5 spacer improves the solubility and bioavailability of drug molecules, while the reactive groups enable the conjugation of therapeutic agents to the delivery vehicle. This can lead to enhanced efficacy and reduced side effects for various medications.
Used in Bioconjugation:
N3-PEG6-tBu is utilized as a bioconjugation agent in the life sciences, allowing for the selective and stable attachment of biological molecules, such as proteins, peptides, or nucleic acids, to other molecular entities. This can be useful for the development of novel diagnostic tools, imaging agents, and therapeutics.
Used in Materials Science:
In the field of materials science, N3-PEG6-tBu is employed as a versatile building block for the development of new materials with tailored properties. The molecule's reactive groups and hydrophilic spacer can be used to create materials with improved mechanical, thermal, or electrical characteristics, as well as enhanced biocompatibility for various applications.

Upstream product

• 1663-39-4 tert-Butyl acrylate 
• 86770-69-6 17-azido-3,6,9,12,15-pentaoxaheptadecan-1-ol 
• 42749-28-0 toluene-4-sulfonic acid 2-[2-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethyl ester 
• 406213-75-0 tert-butyl 1-{[(4-methylphenyl)sulfonyl]oxy}-3,6,9,12,15,18-hexaoxahenicosan-21-oate 
• 2615-15-8 pentaethylene glycol 
• 361189-64-2 tert-butyl 1-hydroxy-3,6,9,12,15,18-hexaoxahenicosan-21-oate 

Downstream Products

• 1286281-32-0 tert-butyl 1-amino-3,6,9,12,15,18-hexaoxahenicosan-21-oate 
• 1352814-10-8 C₂₅H₄₅N₃O₁₀S 
• 1352814-12-0 C₃₁H₄₄F₅N₃O₁₀S 
• 361189-66-4 1-azido-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid 
• 1609108-72-6 pentafluorophenyl 1-bromo-2-oxo-6,9,12,15,18,21-hexaoxa-3-azatetracosan-24-oate 
• 1609108-75-9 N-(24-bromo-23-oxo-4,7,10,13,16,19-hexaoxa-22-azatetracosan-1-oyl)-L-valyl-N-[2-(3-{[trans-4-({[(3R,5S,7R,8R)-8-hydroxy-7-{(1E,3E)-5-[(2S,3S,5R,6R)-5-{[(2Z,4S)-4-hydroxypent-2-enoyl]amino}-3,6-dimethyltetrahydro-2H-pyran-2-yl]-3-methylpenta-1,3-dien-1-yl}-1,6-dioxaspiro[2.5]oct-5-yl]acetyl}amino)cyclohexyl]oxy}-3-oxopropyl)phenyl]-L-alaninamide 
• 905954-28-1 3-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid 
• 882847-13-4 1-{[(tert-butoxy)carbonyl]amino}-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid 

Relevant academic research and scientific papers

Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof

Disclosed are an antibody drug conjugate IB, which uses ether linkages for connection, and improves the water solubility, stability and cytotoxicity in vivo and in intro, and an intermediate, a pharmaceutical composition, and uses of the antibody drug conjugate. The antibody drug conjugate has simple synthetic steps and a high yield.

Expedient synthesis of trifunctional oligoethyleneglycol-amine linkers and their use in the preparation of PEG-based branched platforms

We designed a convergent synthesis pathway that provides access to trifunctional oligoethyleneglycol-amine (OEG-amine) linkers. By applying the reductive coupling of a primary azide to bifunctional OEG-azide precursors, the corresponding symmetrical dialkylamine bearing two homo-functional end chain groups and a central nitrogen was obtained. These building blocks bear minimal structural perturbation compared to the native OEG backbone which makes them attractive for biomedical applications. The NMR investigations of the mechanism process reveal the formation of nitrile and imine intermediates which can react with the reduced free amine form. Additionally, these trifunctional OEG-amine linkers were employed in a coupling reaction to afford branched multifunctional PEG dendrons which are molecularly defined. These discrete PEG-based dendrons (n = 16, 18 and 36) could be useful for numerous applications where multivalency is required.

Target Identification of Yaku'amide B and Its Two Distinct Activities against Mitochondrial FoF1-ATP Synthase

Yaku'amide B (1b) is a structurally unique tetradecapeptide bearing four β,β-dialkylated α,β-unsaturated amino acid residues. Growth-inhibitory profile of 1b against a panel of 39 human cancer cell lines is distinct from those of clinically used anticancer drugs, suggesting a novel mechanism of action. We achieved total syntheses of chemical probes based on 1b and elucidated the cellular target and mode of action of 1b. Fluorescent (3, 4) and biotinylated (5, 6) derivatives of 1b were prepared for cell imaging studies and pull-down assays, respectively. In addition, the unnatural enantiomer of 1b (ent-1b) and its fluorescent probe (ent-3) were synthesized for control experiments. Subcellular localization analysis using 3 and 4 showed that 1b selectively accumulates in the mitochondria of MCF-7 human breast cancer cells. Pull-down assays with 6 revealed FoF1-ATP synthase as the major target protein of 1b. Consistent with these findings, biochemical activity assays showed that 1b inhibits ATP production catalyzed by mitochondrial FoF1-ATP synthase. Remarkably, 1b was also found capable of enhancing the ATP hydrolytic activity of FoF1-ATP synthase. On the other hand, ent-1b inhibits ATP synthesis more weakly than does 1b and does not affect ATP hydrolysis, suggesting the stereospecific requirement for the characteristic multimodal functions of 1b. These findings corroborate that 1b causes growth arrest in MCF-7 cells by inhibiting ATP production and enhancing ATP hydrolysis, thereby depleting the cellular ATP pool. This study provides, for the first time, a structural basis for the design and development of anticancer agents exploiting the novel mode of action of 1b.

SPLICEOSTATIN ANALOGS

The present invention is directed to novel cytotoxic spliceostatin analogs (I) and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.

Synthesis and molecular recognition studies of the HNK-1 trisaccharide and related oligosaccharides. the specificity of monoclonal anti-HNK-1 antibodies as assessed by surface plasmon resonance and STD NMR

The human natural killer cell carbohydrate, HNK-1, plays function-conducive roles in peripheral nerve regeneration and synaptic plasticity. It is also the target of autoantibodies in polyneuropathies. It is thus important to synthesize structurally relate